UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

HemaSphere, 2022-06, Vol.6 (Suppl), p.805-806

2022

Volltextzugriff (PDF)

Cholinergic deficiency in Alzheimer's and Parkinson's disease: Evaluation with pupillometry

International journal of psychophysiology, 2009-08, Vol.73 (2), p.143-149

2009

Volltextzugriff (PDF)

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

Blood cancer journal (New York), 2017-06, Vol.7 (6), p.e570-e570

2017

Volltextzugriff (PDF)

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

Blood cancer journal (New York), 2017-06, Vol.7 (6), p.e571-e571

2017

Volltextzugriff (PDF)

Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis

Bone marrow transplantation (Basingstoke), 2017-11, Vol.52 (11), p.1537-1542

2017

Volltextzugriff (PDF)

P57 PRE‐EXPOSURE PROPHYLAXIS FOR COVID‐19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

HemaSphere, 2023-05, Vol.7 (S2), p.42-42

2023

Volltextzugriff (PDF)

P54 ORAL ANTIVIRALS RITONAVIR‐NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID‐19; A SINGLE‐CENTER, PROSPECTIVE STUDY

HemaSphere, 2023-05, Vol.7 (S2), p.40-41

2023

Volltextzugriff (PDF)

Properties of CA3 dendritic excrescences in Alzheimer's disease

Current Alzheimer research, 2010-02, Vol.7 (1), p.84-90

2010

Volltextzugriff (PDF)

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

HemaSphere, 2023-05, Vol.7 (S2), p.17-18

2023

Volltextzugriff (PDF)

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT‐ELIGIBLE AND ‐INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

HemaSphere, 2023-05, Vol.7 (S2), p.6-7

2023

Volltextzugriff (PDF)

S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY

HemaSphere, 2022-06, Vol.6, p.79-80

2022

Volltextzugriff (PDF)

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

HemaSphere, 2022-06, Vol.6 (Suppl), p.804-805

2022

Volltextzugriff (PDF)

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

Blood cancer journal (New York), 2016-05, Vol.6 (5), p.e428-e428

2016

Volltextzugriff (PDF)

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

Hematology, Transfusion and Cell Therapy, 2020-10, Vol.42, p.22-23

2020

Volltextzugriff (PDF)

Sclerostin Remains Elevated Even in the Plateau Phase of Myeloma Patients: Implications into the Pathogenesis of Osteoblast Dysfunction of Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e229-e229

2015

Volltextzugriff (PDF)

HP57 : Peripheral nerve involvement in AL Amyloidosis : A long prospective follow up study

Clinical neurophysiology, 2022-03, Vol.135, p.e14-e14

2022

Volltextzugriff (PDF)

SP456AUTONOMIC NERVOUS SYSTEM ACTIVITY ASSESSMENT USING PUPILLOMETRY AND HEART RATE VARIABILITY DURING INTRADIALYTIC EXERCISE TRAINING IN HEMODIALYSIS PATIENTS

Nephrology, dialysis, transplantation, 2015-05, Vol.30 (suppl_3), p.iii529-iii530

2015

Volltextzugriff (PDF)

828P Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics

Annals of oncology, 2024-09, Vol.35, p.S607-S607

2024

Volltextzugriff (PDF)

Effect of age on pupillary light reflex: evaluation of pupil mobility for clinical practice and research

Electromyography and clinical neurophysiology, 2007-01, Vol.47 (1), p.11

2007

Volltextzugriff (PDF)

Aortic hemodynamic parameters as predictors of incident or deteriorating hypertension during carfilzomib therapy in patients with relapsed multiple myeloma

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Global deterioration of cardiovascular mechanics by carfilzomib treatment is associated with proteasome activity in patients with relapsed multiple myeloma

European heart journal, 2021-10, Vol.42 (Supplement_1)

2021

Volltextzugriff (PDF)

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

American journal of hematology, 2019-04, Vol.94 (4), p.400-407

2019

Volltextzugriff (PDF)

How We Manage Patients with Plasmacytomas

Current hematologic malignancy reports, 2018-06, Vol.13 (3), p.227-235

2018

Volltextzugriff (PDF)

P30.12: Perinatal outcome in gastroschisis based on prespecified antenatal ultrasound findings

Ultrasound in obstetrics & gynecology, 2012-09, Vol.40 (S1), p.294-294

2012

Volltextzugriff (PDF)

Evaluation of pupil mobility in patients with myasthenia gravis

Electromyography and clinical neurophysiology, 2008-06, Vol.48 (5), p.209

2008

Volltextzugriff (PDF)

1 – 25 von 168

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

P915: EFFICACY AND SAFETY OF DARATUMUMAB MONOTHERAPY IN NEWLY DIAGNOSED PATIENTS WITH STAGE 3B LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

Cholinergic deficiency in Alzheimer's and Parkinson's disease: Evaluation with pupillometry

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib

Outcomes of newly diagnosed myeloma patients requiring dialysis: renal recovery, importance of rapid response and survival benefit

Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxis

P57 PRE‐EXPOSURE PROPHYLAXIS FOR COVID‐19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

P54 ORAL ANTIVIRALS RITONAVIR‐NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID‐19; A SINGLE‐CENTER, PROSPECTIVE STUDY

Properties of CA3 dendritic excrescences in Alzheimer's disease

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT‐ELIGIBLE AND ‐INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

S178: SAFETY AND EFFICACY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH RD IN NEWLY DIAGNOSED, TRANSPLANT INELIGIBLE MULTIPLE MYELOMA PATIENTS: A PHASE 1/2 STUDY BY THE HELLENIC SOCIETY OF HEMATOLOGY

P914: EFFICACY AND SAFETY OF BELANTAMAB MAFODOTIN MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY LIGHT CHAIN AMYLOIDOSIS: A PHASE 2 STUDY BY THE EUROPEAN MYELOMA NETWORK

Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment

Efficacy and safety of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment: results of the phase 2 dare study

Sclerostin Remains Elevated Even in the Plateau Phase of Myeloma Patients: Implications into the Pathogenesis of Osteoblast Dysfunction of Multiple Myeloma

HP57 : Peripheral nerve involvement in AL Amyloidosis : A long prospective follow up study

SP456AUTONOMIC NERVOUS SYSTEM ACTIVITY ASSESSMENT USING PUPILLOMETRY AND HEART RATE VARIABILITY DURING INTRADIALYTIC EXERCISE TRAINING IN HEMODIALYSIS PATIENTS

828P Translocation 11;14 is not associated with adverse prognosis in the era of novel anti-myeloma therapeutics

Effect of age on pupillary light reflex: evaluation of pupil mobility for clinical practice and research

Aortic hemodynamic parameters as predictors of incident or deteriorating hypertension during carfilzomib therapy in patients with relapsed multiple myeloma

Global deterioration of cardiovascular mechanics by carfilzomib treatment is associated with proteasome activity in patients with relapsed multiple myeloma

Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates

How We Manage Patients with Plasmacytomas

P30.12: Perinatal outcome in gastroschisis based on prespecified antenatal ultrasound findings

Evaluation of pupil mobility in patients with myasthenia gravis

Suchergebnisse filtern